Pseudomonas aeruginosa

PreclinicalSmall molecule

Pseudomonas aeruginosa is one of 2 small molecule programs targeting Pseudomonas Aeruginosa. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Pseudomonas AeruginosaEnrolling by invitation

Pseudomonas AeruginosaPreclinical

Enrolling by invitation

Competition

Competitive Landscape

3 competitors in Pseudomonas Aeruginosa

#DrugCompanyPhaseTrials

AZD0292

AstraZeneca

Phase 2

2 2

Pseudomonas aeruginosa

QQilu Hospital of Shandong University

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Bladder Cancer1 trial

Efficacy and Safety of Pseudomonas Aeruginosa for Intermediate and High-risk Non-muscle Invasive Bladder Cancer

Unknown status·QQilu Hospital of Shandong University·Phase 2·NCT05975151·63 enrolled

Pseudomonas Aeruginosa1 trial

Pseudomonas Aeruginosa Injection Combined With Polyvinylpyrrolidone-Iodine in Immediate Breast Reconstruction Surgery With Implants

Enrolling by invitation·JJianyi Li·N/A·NCT07460297·100 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Pseudomonas aeruginosa. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Pseudomonas aeruginosa compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Pseudomonas aeruginosa. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Qilu Hospital of Shandong University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: QQilu Hospital of Shandong University

Pseudomonas aeruginosa

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Bladder Cancer1 trial

Pseudomonas Aeruginosa1 trial

References

Drug Info

Quick Facts

Related News